Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associated with bipolar I disorder, the purpose of this study is to evaluate the change in disease state and safety of cariprazine in the treatment of depressive episodes associated with bipolar I disorder in the pediatric population.
CONTACT US ABOUT DEPRESSIVE BIPOLARDepressive Bipolar Study (Youth 10-17)
Description
Eligibility Criteria
10-17 Years of Age; Diagnosis of bipolar I disorder; Has experienced at least one manic episode in lifetime
Intervention
Participants will receive flexible dose Cariprazine over a 6 week treatment period.
Duration
6 Weeks
Compensation
$50/Visit
Categories
- Youth Clinical Trial